Human embryos generated from abnormal fertilization are usually discarded in assisted reproductive technologies (ART) practice. This study aims to investigate the potential of developing into blastocysts and the chromosomal constitution of tripronuclear (3PN) zygotes. Material and Methods: This study consists of patients who had at least one 3PN embryo after a conventional ART cycle and a subsequent preimplantation genetic testing for aneuploidy (PGT-A) between 2020 and 2022 in our IVF unit. Demographic data, cycle outcomes, blastulation and euploidy rates of 3PN zygotes were retrospectively analyzed. Results: Among 108 patients with a history of PGT-A for diverse indications, 17 had a total of 29 embryos with abnormal pronuclei (3PN). Of those, 9 embryos achieved to develop into a blastocyst and, 6 of them were furtherly evaluated with a fluorescence in situ hybridization (FISH) analysis. The ratio of 3PN embryos to all fertilized embryos (3PN/2PN+3PN) was %21. Although 31% of 3PN embryos reached to the blastocyst stage, all of the biopsied embryos were reported to be aneuploid and clinically discarded later. Conclusion: Based on the low/null euploidy rate; it is mandatory to perform PGT-A before the transfer of a 3PN-derived embryo, particularly in poor prognosis patients with a limited number of embryos. Instead of genetic analysis, routine discard of 3PN-derived blastocysts would be more cost-effective in women with normal ovarian response. Further randomized prospective studies are required to determine the subgroup of patients who could benefit more from genetic testing of 3PN zygotes.